AMLX vs PRTA vs IONS vs BIIB vs RARE vs JPM

For growth investors, Ionis Pharmaceuticals, Inc.

(IONS) is the stronger pick with 33. 9% revenue growth year-over-year, versus -100. 0% for Amylyx Pharmaceuticals, Inc. (AMLX). JPMorgan Chase & Co. (JPM) offers the better valuation at 16. 0x trailing P/E (14. 4x forward), making it the more compelling value choice. Analysts rate Amylyx Pharmaceuticals, Inc. (AMLX) a "Buy" — based on 11 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, JPMorgan Chase & Co.

(JPM) is the cheapest at 16. 0x versus Biogen Inc. at 22. 7x. On forward P/E, Biogen Inc. is actually cheaper at 13. 7x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, JPMorgan Chase & Co.

(JPM) delivered a total return of +118. 2%, compared to -82. 7% for Prothena Corporation plc (PRTA). Over 10 years, the gap is even starker: JPM returned +465. 8% versus PRTA's -82. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Biogen Inc.

(BIIB) is the lower-risk stock at 0. 40β versus Prothena Corporation plc's 1. 50β — meaning PRTA is approximately 271% more volatile than BIIB relative to the S&P 500. On balance sheet safety, Amylyx Pharmaceuticals, Inc. (AMLX) carries a lower debt/equity ratio of 2% versus 5% for Ionis Pharmaceuticals, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Ionis Pharmaceuticals, Inc.

(IONS) is pulling ahead at 33. 9% versus -100. 0% for Amylyx Pharmaceuticals, Inc. (AMLX). On earnings-per-share growth, the picture is similar: Amylyx Pharmaceuticals, Inc. grew EPS 65. 5% year-over-year, compared to -99. 6% for Prothena Corporation plc. Over a 3-year CAGR, RARE leads at 22. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

JPMorgan Chase & Co.

(JPM) is the more profitable company, earning 20. 4% net margin versus -25. 2% for Prothena Corporation plc — meaning it keeps 20. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: JPM leads at 26. 0% versus -1905. 8% for PRTA. At the gross margin level — before operating expenses — IONS leads at 98. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Biogen Inc.

(BIIB) trades at 13. 7x forward P/E versus 176. 7x for Prothena Corporation plc — 163. 0x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for PRTA: 130. 3% to $19. 00.

In this comparison, JPM (1.

9% yield) pays a dividend. AMLX, PRTA, IONS, BIIB, RARE do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, JPMorgan Chase & Co.

(JPM) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 94), 1. 9% yield, +465. 8% 10Y return). Prothena Corporation plc (PRTA) carries a higher beta of 1. 50 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (JPM: +465. 8%, PRTA: -82. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (AMLX (Healthcare) and PRTA (Healthcare) and IONS (Healthcare) and BIIB (Healthcare) and RARE (Healthcare) and JPM (Financial Services)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: AMLX is a small-cap quality compounder stock; PRTA is a small-cap quality compounder stock; IONS is a mid-cap high-growth stock; BIIB is a mid-cap quality compounder stock; RARE is a small-cap high-growth stock; JPM is a large-cap deep-value stock. JPM pays a dividend while AMLX, PRTA, IONS, BIIB, RARE do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.